Adma Biologics EV/EBIT ADMA

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2024.

Today, Oct 23, 2026: 10.9×
3-year median: 29.1×
Against its 3-year history: 17th; percentile: 0 is its lowest day, 100 its highest
3-year range: 8.9× to 76.0×
Peer median: 18.2×

Adma Biologics' EV/EBIT is 10.9× as of Oct 23, 2026.

That is below its 3-year median of 29.1×, lower than on 83% of days in the last 3 years.

Over that time it ranged from 8.9× in Jun 2026 to 76.0× in May 2024.

The median for 9 biotech stocks of a similar size is 18.2×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	10.9×	8.9×	25.6×
2025	27.5×	20.8×	40.0×
2024	36.1×	36.0×	76.0×

Against its peers

Companies in Biotechnology nearest Adma Biologics' size, closest first, today.

Company	EV/EBIT
ADMAAdma Biologics	10.9×
VCELVericel	116×
MGTXMeiraGTx	4.6×
KRYSKrystal Biotech	42.4×
RGENRepligen	160×
TECHBIO-TECHNE	44.9×
HALOHalozyme Therapeutics	17.4×
NBIXNeurocrine Biosciences	18.2×
EXELExelixis	15.4×
INCYIncyte	10.1×
Peer median	18.2×

Where Adma Biologics ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Adma Biologics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.